Publicaciones en las que colabora con PALOMA MERINO AMADOR (26)

2024

  1. Fluconazole-resistant Candida parapsilosis genotypes from hospitals located in five Spanish cities and one in Italy: Description of azole-resistance profiles associated with the Y132F ERG11p substitution

    Mycoses, Vol. 67, Núm. 3

2023

  1. Antifungal resistance in Candida spp within the intra-abdominal cavity: study of resistance acquisition in patients with serial isolates

    Clinical Microbiology and Infection, Vol. 29, Núm. 12, pp. 1604.e1-1604.e6

2022

  1. Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes Spreading across Hospitals Located in Madrid, Spain and Harboring the Y132F ERG11p Substitution

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 8

2021

  1. Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection

    Clinical Microbiology and Infection, Vol. 27, Núm. 5, pp. 758-761

2020

  1. An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 3, pp. 730-737

  2. Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child–Pugh B or C Liver Disease: A Case–Control Retrospective Study

    Infectious Diseases and Therapy, Vol. 9, Núm. 1, pp. 151-163

  3. Factors associated with the development of septic shock in patients with candidemia: A post hoc analysis from two prospective cohorts

    Critical Care, Vol. 24, Núm. 1

  4. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

    The Lancet, Vol. 396, Núm. 10250, pp. 535-544

2019

  1. Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome

    Transplant Infectious Disease, Vol. 21, Núm. 6

  2. Recommendations from a panel of experts on the usefulness of fidaxomicin for the treatment of infections caused by Clostridium difficile

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 1, pp. 50-59

  3. Usefulness of guideline recommendations for prognosis in patients with candidemia

    Medical mycology, Vol. 57, Núm. 6, pp. 659-667

2018

  1. T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: A prospective pilot study

    Journal of Antimicrobial Chemotherapy, Vol. 73, pp. iv6-iv12

  2. T2MR contributes to the very early diagnosis of complicated candidaemia. A prospective study

    Journal of Antimicrobial Chemotherapy, Vol. 73, pp. iv13-iv19

2017

  1. Epidemiology and prognosis of candidaemia in elderly patients

    Mycoses, Vol. 60, Núm. 12, pp. 808-817

  2. Etestw versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: Results from PREMIUM, a European multicentre study

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 2, pp. 431-436

  3. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia

    Clinical Microbiology and Infection, Vol. 23, Núm. 1, pp. 49.e1-49.e8

  4. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance

    Clinical Microbiology and Infection, Vol. 23, Núm. 9, pp. 672.e1-672.e11

  5. Is routine ophthalmoscopy really necessary in candidemic patients?

    PLoS ONE, Vol. 12, Núm. 10

  6. No evidence of increased ocular involvement in candidemic patients initially treated with echinocandins

    Diagnostic Microbiology and Infectious Disease, Vol. 88, Núm. 2, pp. 141-144

2016

  1. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort

    Clinical Microbiology and Infection, Vol. 22, Núm. 8, pp. 733.e1-733.e8